People taking GLP-1 drugs deserve to know exactly what is being injected into their bodies.The FDA warned Harbin Jixianglong Biotech, a Chinese manufacturer tied to GLP-1 active pharmaceutical ingredients, over serious manufacturing and labeling violations. Most alarming, the company was placed on the agency’s GLP-1 API “Green List,” a designation meant to identify manufacturers meeting FDA standards, and then allegedly purchased semaglutide from facilities not on that list, relabeled it as its own, and shipped it toward the U.S. market, according to the FDA.
NAME TWEAK COULD BOOST GLP-1 ACCESS FOR ONE IN EIGHT WOMEN SUFFERING PMOS
That is not a clerical error. That is a direct threat to patients.
If the FDA’s findings are correct, a foreign company used the FDA’s own trusted designation to move GLP-1 ingredients of unknown origin into the American drug supply. Patients may believe they are receiving a safe, reliable medicine. Instead, they could be exposed to foreign substances with unknown sourcing, unknown handling, unknown quality controls, and unknown risks.
This raises a basic question: Why does this Green List even exist?
